
CLAIMS

What is claimed is:

1. A composition comprising:

(i) a bis-mesylate salt of a compound of Formula I:



(I),

or a hydrate thereof, and

(ii) at least one pharmaceutically acceptable carrier.

2. The composition of claim 1, wherein the bis-mesylate salt is a monohydrate, bis-mesylate salt of the compound of Formula I.

3. The composition of claim 1 or 2, wherein the bis-mesylate salt is a polymorph having an X-ray diffraction pattern comprising 2θ-reflections, plus or minus 0.2 degrees 2θ, at 7.7, 12.9, 17.7, and 18.1.

4. The composition of claim 3, wherein the bis-mesylate salt is a polymorph having an X-ray diffraction pattern further comprising 2θ-reflections, plus or minus 0.2 degrees 2θ, at 13.8, 16.9, 22.9 and 26.1.

5. The composition of any one of claims 1 to 4, further comprising methanesulfonic acid.

6. The composition of any one of claims 1 to 5, wherein the at least one pharmaceutically acceptable carrier is at least one pharmaceutically acceptable polymer.

7. The composition of claim 6, wherein the at least one pharmaceutically acceptable polymer is a precipitation inhibitor.

8. The composition of claim 6, wherein the at least one pharmaceutically acceptable polymer is non-ionic.

9. The composition of claim 6, wherein the at least one pharmaceutically acceptable polymer is selected from the group consisting of hydroxypropylmethylcellulose, copovidone, povidone, methyl cellulose, hydroxyethylcellulose, hydroxypropylcellulose, ethylcellulose, pyroxylin, polyethylene oxide, polyvinyl alcohol, polyethylene glycol, and polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol.

10. The composition of claim 9, wherein the at least one pharmaceutically acceptable polymer is hydroxypropylmethylcellulose.

11. The composition of any one of claims 5 to 10, wherein the composition comprises a polymer matrix obtainable from the at least one pharmaceutically acceptable polymer.

12. The composition of claim 11, wherein the compound of Formula I, or a cation thereof, and the methanesulfonic acid, or an anion thereof, are dispersed within the polymer matrix.

13. The composition of any one of claims 1 to 12, further comprising water.

14. The composition of any one of claims 1, 2 and 5 to 13, wherein the composition is a feed solution for spray drying.

15. The composition of any one of claims 1, 2 and 5 to 12, wherein the composition is a spray-dried powder.

16. The composition of claim 15, wherein the powder is non-crystalline.

17. The composition of claim 15, wherein the powder is characterized by an X-ray diffraction pattern comprising 2θ-reflections, plus or minus 0.2 degrees 2θ, at 6.3 and between 26.1 to 26.6.

18. The composition of any one of claims 1 to 12 and 15 to 17, wherein the composition is a tablet.

19. The composition of claim 18, further comprising at least one diluent, binder, disintegrant, surfactant, glidant, or lubricant, or any combinations thereof.


20. The composition of claim 19, wherein one of the at least one diluent is mannitol.

21. The composition of any one of claims 18 to 20, further comprising any one or more of crospovidone, poloxamer, colloidal silicon dioxide, magnesium stearate, and microcrystalline cellulose.

22. A method of manufacturing a tablet, comprising:

a) forming spray-dried powder from a feed solution, wherein the feed solution comprises:

(i) a compound of Formula I:



(I),

or a cation thereof;

(ii) methanesulfonic acid, or an anion thereof;

(iii) at least one pharmaceutically acceptable carrier; and

(iv) water; and

b) dry granulating the spray-dried powder and at least one additional pharmaceutically acceptable carrier to form a granulation; and

c) compressing the granulation to form the tablet;

wherein the methanesulfonic acid or an anion thereof, and the compound of Formula I or a cation thereof, are present in the feed solution in a molar ratio of the methanesulfonic acid or an anion thereof, to the compound of Formula I or a cation thereof, of between 2 : 1 and 3 : 1.


23. The method of claim 22, wherein the mesylate salt of the compound of Formula I is a bis-mesylate salt of the compound of Formula I, or a hydrate thereof.

24. The method of claim 23, wherein the mesylate salt is a monohydrate, bis-mesylate salt of the compound of Formula I.

25. A method of manufacturing a tablet, comprising:

a) dry granulating:

(i) a bis-mesylate salt of a compound of Formula I:



(I),

or a hydrate thereof, and

(ii) at least one pharmaceutically acceptable carrier

to form a granulation; and

b) compressing the granulation to form the tablet.

26. A tablet produced according to the method of any one of claims 22 to 25.

27. A unit dosage form comprising the composition of any one of claims 1 to 12 and 15 to 21, or the tablet of claim 26.

28. An article of manufacture comprising the composition of any one of claims 1 to 12 and 15 to 21, or the tablet of claim 26, or a unit dosage form of claim 27.

29. Use of a therapeutically effective amount of a composition of claims 1 to 12 and 15 to 21, or therapeutically effective amount of a tablet of claim 26, or therapeutically effective amount of a unit dosage form of claim 27 in the manufacture of a medicament for treating a condition mediated by Syk activity in a human in need thereof, wherein the condition is selected from the group consisting of cancer and autoimmune disease.

30. The use of claim 29, wherein the condition is selected from the group consisting of acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), myelodysplastic syndrome (MDS), myeloproliferative disease (MPD), chronic myeloid leukemia (CML), multiple myeloma (MM), non-Hodgkin's lymphoma (NHL), mantle cell lymphoma (MCL), follicular lymphoma (FL), Waldestrom's macroglobulinemia (WM), T-cell lymphoma, B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), lymphoplasmacytic lymphoma (LPL), and marginal zone lymphoma (MZL).

31. The use of claim 30, wherein the condition is non-Hodgkin's lymphoma (NHL).

32. The use of claim 31, wherein the NHL is indolent non-Hodgkin's lymphoma (iNHL).

33. The use of claim 32, wherein the iNHL is refractory iNHL.

34. The use of claim 32, wherein the iNHL is non-FL iNHL.

35. The use of claim 29, wherein the condition is selected from the group consisting of asthma, rheumatoid arthritis, multiple sclerosis, and lupus.

36. The use of claim 30, wherein the condition is acute lymphocytic leukemia (ALL).

37. The use of claim 30, wherein the condition is acute myeloid leukemia (AML).

38. The use of claim 30, wherein the condition is chronic lymphocytic leukemia (CLL).

39. The use of claim 30, wherein the condition is small lymphocytic lymphoma (SLL).

40. The use of claim 30, wherein the condition is myelodysplastic syndrome (MDS).

41. The use of claim 30, wherein the condition is myeloproliferative disease (MPD).

42. The use of claim 30, wherein the condition is chronic myeloid leukemia (CML).

43. The use of claim 30, wherein the condition is multiple myeloma (MM).

44. The use of claim 30, wherein the condition is mantle cell lymphoma (MCL).

45. The use of claim 30, wherein the condition is follicular lymphoma (FL).

46. The use of claim 30, wherein the condition is Waldestrom's macroglobulinemia (WM).

47. The use of claim 30, wherein the condition is T-cell lymphoma, B-cell lymphoma.

48. The use of claim 30, wherein the condition is diffuse large B-cell lymphoma (DLBCL).

49. The use of claim 30, wherein the condition is lymphoplasmacytic lymphoma (LPL).

50. The use of claim 30, wherein the condition is and marginal zone lymphoma (MZL).